tuneTypical Dose
15-30 mL per day (1-2 tablespoons)
Natural Compound
Coconut oil
Cocos nucifera oil (MCT-rich saturated fat)
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
Acute (1-2 hours) for energy/ketone production. 4+ weeks for measurable lipid changes.
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Coconut oil is a saturated-fat-rich oil containing medium-chain triglycerides and lauric acid. It is used as a dietary fat for energy, satiety, and antimicrobial-related claims.
Broader coconut-oil evidence still supports LDL caution when it replaces unsaturated oils, but a newer virgin-coconut-oil meta-analysis suggests a narrower phenotype with higher HDL and lower triglycerides and little else. That does not make coconut oil a cardioprotective fat. It means virgin coconut oil may have a slightly less unfavorable metabolic profile than generic coconut-oil messaging implies, while still lacking convincing benefits for glucose, blood pressure, weight, or inflammation.
Contains MCTs (primarily lauric acid C12) that undergo hepatic beta-oxidation and partial ketogenesis. Lauric acid raises both LDL and HDL via increased hepatic cholesterol synthesis.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Raises HDL cholesterol (+4.00 mg/dL vs non-tropical oils)
- Raises LDL cholesterol (+10.47 mg/dL vs non-tropical oils)
Secondary Outcomes
- Mild ketone production from MCT fraction
- Improved absorption of fat-soluble supplements
Safety
Contraindications and Interactions
Contraindications
- Familial hypercholesterolemia
- Established CVD on lipid-lowering therapy
Side effects
- Diarrhea
- Stomach cramps
- Elevated LDL cholesterol
Interactions
- May counteract lipid-lowering medications (statins) by raising LDL
Avoid if
- High baseline LDL
- Statin therapy with LDL not at target
- Coconut allergy
Evidence
Study-level References
coconut-oil-SRC-001Meta-analysis
Sourceopen_in_newNeelakantan N, et al. "The Effect of Coconut Oil Consumption on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis of Clinical Trials." Circulation. 2020.
Population: General adults
Dose protocol: Dietary replacement trials, typically 2-4 tbsp/day for 4-12 weeks
Key findings: Coconut oil consumption significantly increased LDL-cholesterol by 10.47 mg/dL and HDL-cholesterol by 4.00 mg/dL compared with non-tropical vegetable oils.
Notes: Meta-analysis of 16 trials. Consistent LDL-raising effect across studies. HDL rise does not necessarily offset cardiovascular risk.
Paper content
Coconut oil consumption significantly increased LDL-cholesterol by 10.47 mg/dL and HDL-cholesterol by 4.00 mg/dL compared with non-tropical vegetable oils.
coconut-oil-SRC-002Systematic review and meta-analysis
Sourceopen_in_newThe effect of virgin coconut oil (VCO) on cardiovascular disease risk factors: a systematic review and meta-analysis. Diabetol Metab Syndr. 2025. doi:10.1186/s13098-025-02019-6. PMID:41444640.
Population: Adults enrolled in virgin coconut oil supplementation randomized controlled trials.
Dose protocol: Virgin coconut oil across 14 adult RCTs lasting 2 to 24 weeks
Key findings: VCO lowered triglycerides by about 12 mg/dL and increased HDL-C by about 8 mg/dL, with no clear effect on fasting glucose, body size, blood pressure, CRP, or most other lipid markers.
Notes: Useful corrective study because it narrows any cardiometabolic claim to specific lipid shifts rather than broad heart-health benefit.
Paper content
Virgin coconut oil improved triglycerides and HDL cholesterol in pooled adult trials, but it did not improve most other cardiometabolic markers. This is a corrective modernization study because it narrows any benefit claim to specific lipid shifts and avoids broad heart-health framing.